Argos Therapeutics Inc. (ARGS) Shares Down 4.2%
Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) dropped 4.2% during trading on Monday . The stock traded as low as $4.48 and last traded at $4.51, with a volume of 195,412 shares. The stock had previously closed at $4.71.
ARGS has been the subject of several analyst reports. Roth Capital increased their price objective on Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, April 19th. Needham & Company LLC reissued a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, April 23rd. Zacks Investment Research downgraded Argos Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. FBR & Co reissued a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, May 14th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research note on Monday, June 20th. Eight equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $11.50.
The company’s 50 day moving average price is $5.65 and its 200 day moving average price is $5.86. The firm’s market capitalization is $109.74 million.
Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, analysts anticipate that Argos Therapeutics Inc. will post ($1.49) EPS for the current fiscal year.
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.